FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 111 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... November 3, 2020 Perguntas frequentes sobre COVID-19 e câncer: respostas para pacientes e sobreviventes June 23, 2020 How Do Black People with Cancer View Clinical Research? November 15, 2024 EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... March 13, 2024 Load more HOT NEWS FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer ΤΙ ΕΙΝΑΙ Study Shows CAR T-Cell Therapy Is Effective at Putting Childhood Leukemia... Feasibility and Safety of Preoperative Treatment with Nivolumab and Relatlimab in...
